Loading this company
Ligand Pharmaceuticals Incorporated
LGNDPrices in USD
TickerWorth ScoreC53/100
What we think
Priced above our range of $86.65 to $134.70.
Price
$300.05USD up +$4.51 (+1.53%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 14:47 UTC (5 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 2 models, on today’s numbers
$86.65–$134.70
What the price needs: revenue growth of more than 25%/yr for 5 years (our model assumes 16.6%), or investors accepting a ~3.6% discount rate, vs the 8.7% our model uses.
Led by peer multiples (P/E, EV/EBITDA, P/S) · Fast grower
Price $300.05Priced · Prices are delayed.
Is it a good business?
- Valuation17 out of 100
- Growth100 out of 100
- Financial health83 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$344.25 across 12 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 47 people.
Key stats
52-week range$175.89–$326.63
- Open
- $300.41
- Day high
- $303.86
- Day low
- $299.46
- Previous close
- $295.54
- Volume
- 10,861 · 0.04× avg
- Average volume
- 249,845
- Market cap
- $5,981,679,104.00
- P/E (TTM)
- 31.62
- Earnings per share
- $9.49
- Beta
- 1.01
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Disclosed another material event
- Issued a public disclosure (Reg FD)
- Reported quarterly or annual results
- Completed an acquisition or sale of assets
- Signed a material agreement
- Signed a material agreement
- Changed leadership or its board
Top news
No recent headlines we can cite for this company.
Insider trades
No insider filings for this company in the recent window.
Not investment advice. TickerWorth Score is a model output.